B. Riley downgraded shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) from a buy rating to a neutral rating in a research note published on Monday morning, Marketbeat Ratings reports. They currently have $60.00 price objective on the biotechnology company’s stock, down from their previous price objective of $65.00. Other research analysts also recently issued […]
JMP Securities lowered shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) from an outperform rating to a market perform rating in a research note published on Monday, Marketbeat reports. Several other equities research analysts have also recently commented on the company. Citigroup upgraded Mirati Therapeutics from a neutral rating to a buy rating and cut […]
Scotiabank upgraded shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) from an underperform rating to a sector perform rating in a research report sent to investors on Monday morning, MarketBeat reports. The firm currently has $58.00 target price on the biotechnology company’s stock. Other research analysts also recently issued research reports about the company. JMP […]
Exxon and Chevron shares rise after a surge in oil prices following the weekend attack on Israel from Hamas, Lockheed and other defense stocks jump following.
Mirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its.